Pfizer joins the Open Targets consortium

14 February 2022

Open Targets, a consortium focused on drug target identification, prioritisation, and validation, announced today that Pfizer has joined as a partner. Pfizer will contribute its unique expertise in oncology, immunology, and metabolic disorders as part of the innovative public-private partnership which uses human genetics and genomics data with the aim of improving the success rate for developing new medicines. This complements the strengths of the five current partners: EMBL’s European Bio...

Read more


Locus-to-Gene method published in Nature Genetics

28 October 2021

Our locus-to-gene (L2G) machine learning scoring method was published in Nature Genetics (the preprint is also available). The L2G score reflects the likelihood that a gene is causal for the trait in question, allowing genes at trait-associated loci to be ranked by the relative strength of their evidence. It has been included in the Genetics portal since version 4.

Read more


Open Targets releases a COVID-19 Target Prioritisation Tool

29 July 2020

Open Targets is excited to announce the release of our COVID-19 Target Prioritisation Tool, an interactive, open source web portal that integrates a number of key public datasets and publications to facilitate systematic exploration of host and viral targets as well as potential treatments for COVID-19.

Read more


Open Targets Helix logo and wordmark

Gosia Trynka awarded 2020 Leena Peltonen Prize

6 June 2020

Open Targets is excited to announce that Gosia Trynka, our Experimental Science Director, has been awarded the 2020 Leena Peltonen prize by the European Society for Human Genetics (ESHG).

The prize is given every two years to an outstanding young researcher in the field of human genetics and it honours the memory of Dr. ...

Read more